NASDAQ: SCNXScienture Holdings Inc Stock
$0.45+0.00 (+0%)
Updated Feb 2, 2026
SCNX Price
$0.45
Fair Value Price
N/A
Market Cap
$18.41M
52 Week Low
$0.43
52 Week High
$3.80
P/E
-0.05x
P/B
0.22x
P/S
24.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$653.39k
Earnings
-$20.55M
Gross Margin
88.5%
Operating Margin
-2,593.64%
Profit Margin
-3,145.8%
Debt to Equity
0.27
Operating Cash Flow
-$11M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCNX Overview
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics and independent pharmacies. TRxADE HEALTH, Inc. is headquartered in Tampa, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCNX's potential to beat the market
- SCNX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
F
SCNX
RankedUnranked of 2
RankedUnranked of 2
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.25 | C | |
| $3.07 | F | |
| $0.77 | – |
Be the first to know about important SCNX news, forecast changes, insider trades & much more!
SCNX News
Overview
Due Diligence Score
–
Industry Average (18)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCNX is good value based on its book value relative to its share price (0.22x), compared to the US Pharmaceutical Retailers industry average (-2.17x)
P/B vs Industry Valuation
SCNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SCNX due diligence checks available for Premium users.
Valuation
SCNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
-7.69x
Market
42.86x
SCNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.22x
Industry
-2.17x
SCNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCNX's financial health
Profit margin
Revenue
$590.1k
Net Income
-$3.6M
Profit Margin
-611.4%
SCNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$104.8M
Liabilities
$22.2M
Debt to equity
0.27
SCNX's short-term liabilities ($7.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCNX's long-term liabilities ($14.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$0.0
Financing
$3.6M
SCNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCNX vs Pharmaceutical Retailer Stocks
Scienture Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.